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Abstract
In clinical trials, minimum clinically important difference (MCID) has attracted increasing
interest as an important supportive clinical and statistical inference tool. Many estimation
methods have been developed based on various intuitions, while little theoretical justification
has been established. This paper proposes a new estimation framework of MCID using both
diagnostic measurements and patient-reported outcomes (PRO’s). The framework first formu-
lates population-based MCID as a large margin classification problem, and then extends to
personalized MCID to allow individualized thresholding value for patients whose clinical pro-
files may affect their PRO responses. More importantly, the proposed estimation framework is
showed to be asymptotically consistent, and a finite-sample upper bound is established for its
prediction accuracy compared against the ideal MCID. The advantage of our proposed method
is also demonstrated in a variety of simulated experiments as well as two phase-3 clinical trials.
Keywords: Fisher consistency, margin, minimum clinically important difference, non-convex minimization,
support vector machine
1 Introduction
In clinical trials for drugs or medical devices, statistical significance is widely used to infer the
treatment effect. However, there has been growing recognition that statistical significance could
be misleading when evaluating treatment effect (Jacobson et al., 1984; Jacobson and Truax, 1991).
First, in many trials, the statistical significance of the treatment effect may have little to do with its
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clinical significance. It is known that statistical significance only infers the existence of treatment
effect, regardless of the effect size. Further, the statistical significance could result from a small
sample variability or a huge sample size, and thus provides little information about the clinical
meaningfulness of the treatment (Jacobson and Truax, 1991). Second, the statistical significance
for the treatment group compared to the placebo group ignores the possible heterogeneity among
individuals. For instance, in a pain reduction study, a statistically significant reduction is concluded
for a test treatment while many individual patients in the treatment group actually report little
improvement regarding the pain reduction (Younger et al., 2009).
Clinical significance is desired in practice as it provides a better assessment of the clinically
meaningful improvement. It is often based on the patients’ reports in a community according
to certain external standards (Jacobson and Truax, 1991). One common approach is to collect
patient-reported outcomes (PRO’s; FDA, 2009), such as their satisfaction of a treatment. Some
earlier practice suggested to replace the statistical significance tests by analyzing the PRO’s only,
which is problematic due to the subjective bias in the PRO’s or unreliability of a poorly designed
questionnaire. Minimum clinically important difference (MCID) was discussed in Jaeschke et
al. (1989), which was intuitively defined as a thresholding value in post-treatment change, and a
patient is considered experiencing a clinically meaningful improvement if her/his change exceeds
the MCID. Copay et al. (2007) suggested to incorporate both certainty of effective treatment and
patients’ satisfactions for determining MCID.
The concept of MCID provides objective reference for clinicians and health policy makers
regarding the effectiveness of the treatment, and has quickly gained its popularity among the prac-
titioners. In 2012, U.S. Food and Drug Administration (FDA) hosted a special conference on the
MCID for orthopaedic devices (http://www.fda.gov/MedicalDevices/NewEvents/
Workshops/Conferences/ucm327292.htm). Although the importance of MCID has been
widely recognized, only a few ad-hoc approaches have been proposed for its estimation with little
theoretical justification (Bennett, 1985; Leisenring and Alonzo, 2000; Shiu and Gatsonis, 2008).
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In this paper, the MCID is formulated as the thresholding value in post-treatment change such
that the probability of disagreement between the estimated satisfaction based on the MCID and the
PRO is minimized. With this framework, two scenarios are considered: population-based MCID
and personalized MCID. The population-based MCID is the ideal thresholding value for the gen-
eral population, and the personalized MCID allows different MCID values for individual patients
based on their clinical profiles. Both scenarios can be formulated in a large margin classification
framework, where the population-based MCID can be estimated via an exhaustive grid search, and
the personalized MCID is modeled in a reproducing kernel Hilbert space and estimated via some
non-convex optimization techniques. Most importantly, the asymptotic properties of the proposed
estimation method are established for both population-based and personalized MCID’s, and their
fast convergence rates to the ideal performance are explicitly quantified.
The rest of the paper is organized as follows. In Section 2, a general framework for the
population-based MCID is presented, and its estimation algorithm and asymptotic properties are
studied. Section 3 extends the framework to the personalized MCID, and discusses the appropriate
large margin loss as well as the efficient non-convex optimization technique. Section 4 establishes
the asymptotic properties of our proposed method for estimating the personalized MCID. Section
5 conducts numerical experiments of our proposed method in simulated examples, and Section
6 applies our proposed method to two phase-3 clinical trial datasets. Section 7 contains some
discussion, and the appendix is devoted to technical proofs.
2 A general framework of MCID
2.1 Formulating MCID
Suppose that a patient’s diagnostic measurement X ∈ R1 is continuously connected, and the
patient-reported outcome (PRO) Y ∈ {−1, 1}, where Y = 1 denotes a clinically meaningful
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treatment reported by the patient and Y = −1 otherwise. Let f(x, y) and f(x) be the joint density
of (X, Y ) and the marginal density ofX , respectively. The MCID is formulated as the thresholding
value c∗ such that sign(X − c∗) agrees with Y as much as possible, where sign(u) = 1 if u ≥ 0
and −1 otherwise. Mathematically, c∗ is defined as a solution of
min
c
P (Y 6= sign(X − c)) = min
c
1
2
E (1− Y sign(X − c)) , (1)
where P (·) is taken with respect to both X and Y .
Lemma 1 Assume that p(x) = P (Y = 1|X = x) is continuous and increasing in x, then the ideal
MCID c∗ satisfies
p(c∗) = P (Y = 1|X = c∗) = 1
2
. (2)
Furthermore, if p(x) is strictly increasing in x, then c∗ is the unique root of (2).
Note that it is reasonable to assume that p(x) is increasing in x since patients with better
diagnostic measurements are expected to be more likely to give positive responses. If p(x) is only
non-decreasing, the equation in (2) may have multiple roots and a conservative choice is to set c∗ as
the largest root. Furthermore, the continuity assumption of p(x) can be relaxed to semi-continuity,
and then the equation in (2) may have no root at all. In such scenarios, it could be proved similarly
as Lemma 1 that c∗ = argminc{p(c) ≥ 1/2}.
It is known that the quality of the PRO’s is largely affected by patients’ subjectivity (Frost
et al., 2007). Such subjectivity is accounted in the proposed formulation of the MCID through
p(x), which can be interpreted as the probability of patient’s telling the truth. For instance, Fang
(2011) considered a special case of semi-continuous p(x), and modeled the subjectivity explicitly
as p(x) = Q when x ≥ c∗ and p(x) = 1 − Q otherwise, where Q > 1
2
measures how trustworthy
the PRO’s are. More importantly, the ideal MCID in (2) is less affected by the subjectivity in the
PRO’s, as it relies on p(x) only when x is in the neighborhood of c∗. This is analogous to the Bayes
rule in classification, which only relies on whether p(x) ≥ 1/2 (Lin, 2002).
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In addition, the MCID has an interesting connection with the median lethal dose in toxicology
research. The median lethal dose refers to the smallest dose required to kill half of the animals that
receive it after a specified test duration. To describe the interaction between dosage and mortality
rate, the logistic dose-response curve is popularly used (Williams, 1986; Alho and Valtonen, 1995;
Kelly, 2001) . It assumes that the mortality rate is expected to strictly increase with dose, which
coincides with our assumption in Lemma 1.
2.2 Estimating MCID
The primary interest of this paper is to estimate the MCID, which is in sharp contrast to the standard
classification that focuses on the classification boundary. In (2), the ideal MCID c∗ is defined
based on p(x) that is often unavailable in practice, so the MCID needs to be estimated based on
the training sample (xi, yi)ni=1.
Naturally, the expectation in (1) can be approximated by its empirical version, and the estimated
MCID cˆ is defined as a solution of
min
c
1
2n
n∑
i=1
(1− yi sign(xi − c)) . (3)
Note that (3) is a simple 1-dimensional optimization problem, and the objective function remains
the same for x(i) ≤ c < x(i+1), where x(i) is the i-th order statistic. Therefore, an exhaustive grid
search scheme can be implemented, and the global minimizer cˆ is simply the xi that yields the
smallest objective function value.
Theorem 1 The estimated MCID cˆ in (3) is a consistent estimate of c∗ if p(x) is continuous and
strictly increasing in x. Further, if there exist positive constants α1, γ1 < 2/α1 + 4/α21, a1 and a2,
5
such that for sufficiently small ξ > 0,
P (|p(X)− p(c∗)| ≤ ξ) ≤ a1ξα1 , (4)
sup
|x−c∗|≤ξ
|p(x)− p(c∗)| ≤ a2ξγ1 , (5)
then |cˆ− c∗| = Op
(
(n log−2 n)−1/(2(1+2/α1)−α1γ1)
)
.
Theorem 1 establishes the asymptotic convergence rate of |cˆ− c∗|, and the finite sample bound
for |cˆ − c∗| can also be obtained as in Appendix A. In Theorem 1, (4) is similar to the low noise
assumption (Polonik, 1995; Bartlett et al., 2003; Tsybakov, 2004) that describes the behavior of X
in the neighborhood of c∗, and (5) is implied by a Ho¨lder continuity condition on p(x). For illustra-
tion, ifX is uniformly distributed on [a, b] and (5) is met with γ1, then (4) can be verified with α1 =
1/γ1 for sufficiently small ξ. Theorem 1 then implies that |cˆ− c∗| = Op
(
(n log−2 n)−1/(1+4γ1)
)
. It
leads to a fast convergence rate when p(x) has a steep derivative at c∗ with γ1 close to 0, and a rate
of Op
(
n−1/3(log n)2/3
)
when (5) holds with order γ1 = 1/2.
2.3 Weighted MCID
In many clinical studies, it is a common practice to be conservative when predicting whether the
test outcome is clinically meaningful. It is then less desirable to predict positive for an unsatisfied
patient than negative for a satisfied patient. To accommodate the unbalanced severity, the weighted
MCID can be introduced with the weights reflecting the severity of the disagreements. Specifically,
the weighted MCID c∗w is defined as a solution of
min
c
1
2
E
(
w(Y ) (1− Y sign(X − c))
)
, (6)
6
where w(1) = w and w(−1) = 1− w. Similarly as in Lemma 1, it can be shown that
p(c∗w) = P (Y = 1|X = c∗w) = 1− w, (7)
where an appropriate choice of w < 1/2 leads to a conservative estimation.
The weighted MCID has another useful interpretation in the context of hypothesis testing. In
particular, we denote the type-I error and type-II error as R0(c) = P (X − c > 0|Y = −1) and
R1(c) = P (X − c < 0|Y = 1), respectively. Then it is natural to find c∗α to solve
min
c
R1(c) subject to R0(c) ≤ α, (8)
where α is the significance level as in the standard hypothesis testing setup. This formulation is
closely related with the Neyman-Pearson classification as discussed in Scott and Nowak (2005) and
Rigollet and Tong (2011). More interestingly, an one-to-one correspondence between the weighted
MCID c∗w in (7) and the solution c
∗
α in (8) can be easily established.
3 Personalized MCID
In many clinical trials, it is commonly believed that patients’ report could be influenced by vari-
ous factors such as their expectation of treatment (Wise, 2004). For instance, in a shoulder pain
reduction study, healthy people demonstrate a higher threshold than those with chronic conditions
due to their expectation of complete recovery. To allow the MCID to vary according to patients’
clinical profiles, this section extends the estimation framework to personalized MCID.
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3.1 Formulation
Let z denote patients’ clinical profiles, and the personalized MCID c∗(z) is formulated as a solution
of
min
c
P (Y 6= sign(X − c(Z))) = min
c
1
2
E (1− Y sign(X − c(Z))) , (9)
where P is taken with respect to (X, Y, Z). Similarly as in (2), we can show that c∗(z) satisfies
pz(c
∗(z)) = P (Y = 1|X = c∗(z), Z = z) = 1
2
, (10)
where pz(x) = P (Y = 1|X = x, Z = z) is assumed to be a continuous and strictly increasing
function in x for any value of z. If only semi-continuity is assumed, the MCID can be formulated
as c∗(z) = argminc{c : pz(c) ≥ 12}. It is worth pointing out that the personalized MCID in (9)
differs from the Bayes rule in classification in that the candidate function in (9) has to take the
form of x− c(z) in order to estimate c∗(z), whereas a Bayes rule in classification searches for the
optimal classification function g(x, z) that may not lead to an explicit estimation of c∗(z).
The formulation in (9) is similar as in (1) with population-based c∗, but the difficulty arises in
the estimation part. Since the empirical version of (9)
min
c
1
2n
n∑
i=1
(
1− yi sign(xi − c(zi))
)
, (11)
involves the 0-1 loss L01(u) = 12(1− sign(u)) and needs to be optimized with respect to functional
c(z), it can no longer be solved by the exhaustive grid search or any other efficient optimization
techniques. Therefore, a surrogate loss function needs to be introduced to replace the 0-1 loss
and facilitate the estimation. The surrogate loss has been widely studied in machine learning
literature. Popularly used surrogate loss functions L(u) include the hinge loss L(u) = (1 − u)+
(Vapnik, 1998), the logistic loss L(u) = log(1 + exp(−u)) (Zhu and Hastie, 2005), and the ψ-
loss min((1 − u)+, 1) (Shen et al., 2003; Liu and Shen, 2006). However, all these losses are not
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generally Fisher consistent in estimating c∗(z), as the candidate function in (9) is restricted to the
form of x− c(z) for estimating MCID. Counter examples can be constructed as in Appendix B.
In this paper, we propose a novel surrogate loss, ψδ-loss, which is defined as
Lδ(u) = min
(
1
δ
(δ − u)+, 1
)
. (12)
The ψδ-loss extends the ψ-loss by introducing a new parameter δ that controls the difference be-
tween the surrogate loss and the 0-1 loss. More importantly, Lemma 2 shows that the ψδ-loss is
asymptotically Fisher consistent in estimating c∗(z) when δ converges to 0.
Lemma 2 For any given z, if the conditional density fz(x) is continuous and pz(x) is strictly
increasing in x, then E
(
Lδ(Y (X− c))|Z = z
)
converges to E
(
L01(Y (X− c))|Z = z
)
as δ → 0
uniformly over a compact set Dz containing c∗(z) and
argmin
c
E
(
Lδ(Y (X − c(z)))|Z = z
)
−→ c∗(z).
With the ψδ-loss, the proposed estimation formulation for the personalized MCID cˆ(z) solves
min
c∈F
1
n
n∑
i=1
Lδ(yi(xi − c(zi))) + λJ(c), (13)
where λ is a tuning parameter, J(c) is a penalty term, and F is set as a reproducing kernel Hilbert
space (RKHS; Wahba, 1990). The final estimation formulation then becomes
min
c∈HK
1
n
n∑
i=1
Lδ(yi(xi − c(zi))) + λ
2
‖c‖2HK , (14)
whereHK is the RKHS induced by some pre-specified kernel functionK(·, ·), and J(c) = 12‖c‖2HK
is the associated RKHS norm of c(z). It follows from the representer theorem (Wahba, 1990) that
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the solution to (14) is of the form cˆ(z) = b +
∑n
i=1wiK(zi, z), and thus ‖c‖2HK = wTKw with
w = (w1, · · · , wn)T andK = (K(zi, zj))ni,j=1.
3.2 Non-convex optimization
Note that the cost function in (14) is non-convex, and thus we employ the difference convex algo-
rithm (DCA; An and Tao, 1997) to tackle the non-convex optimization. The key idea of the DCA
is to decompose the non-convex cost function into the difference of two convex functions, and then
construct a sequence of subproblems by approximating the second convex function with its affine
minorization function.
In particular, the ψδ-loss is decomposed as
Lδ(u) = min
(
1
δ
(δ − u)+, 1
)
=
1
δ
(δ − u)+ − 1
δ
(−u)+.
Then the cost function in (14) can be decomposed as s(w) = s1(w)− s2(w), where
s(w) =
1
n
n∑
i=1
Lδ(yi(xi − c(zi))) + λ
2
‖c‖2HK ,
s1(w) =
1
n
n∑
i=1
(1
δ
(δ − yi(xi − c(zi)))+
)
+
λ
2
‖c‖2HK ,
s2(w) =
1
n
n∑
i=1
(1
δ
(−yi(xi − c(zi)))+
)
,
and w is the coefficient vector for the RKHS representation of c(z).
Next, the DCA constructs a sequence of decreasing upper envelop of s(w) by approximating
s2(w) with its affine minorization function, s2(w(k)) + 〈w − w(k),∇s2(w(k))〉, where w(k) is the
estimated w at the k-th iteration, and ∇s2(w(k)) is the subgradient of s2(w) at w(k). The updated
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w(k+1) is then obtained by solving
w(k+1) = argmin
w
s1(w)− s2(w(k))− 〈w − w(k),∇s2(w(k))〉. (15)
The updating scheme is iterated until convergence. Although the DCA cannot guarantee global
optimum, it delivers a superior numerical performance as demonstrated in the extensive simulation
study in Liu et al. (2005).
4 Asymptotic theory
This section quantifies the asymptotic behavior of cˆ(z) in estimating the personalized MCID. De-
note eδn(cˆ, c∗) = E
(
Lδn(Y (X − cˆ(Z))) − Lδn(Y (X − c∗(Z)))
)
with δn > 0, where δ and λ are
rewritten as δn and λn to denote their dependency on n. We make the following four technical
assumptions.
Assumption A. For some positive sequence sn → 0 as n → ∞, there exists c0(z) ∈ F , such
that for sufficiently small δn, eδn(c0, c∗) ≤ sn. That is, inf{c∈F} eδn(c, c∗) ≤ sn.
Assumption A is standard (Shen et al., 2003; Li et al., 2007), and describes the approximation
error of F in approximating c∗(z).
Assumption B. There exist constants 0 < α2 < +∞ and a3 > 0 such that for any given z,
P (|pz(X)− pz(c∗(z))| ≤ ξ) ≤ a3ξα2 for sufficiently small ξ.
Assumption B is the low noise assumption that describes the distribution of the diagnostic
outcome X in the neighborhood of c∗(z).
Assumption C. There exist constants 0 < γ2 < +∞ and a4 > 0 such that for any given z,
sup|x−c∗(z)|≤ξ |pz(x)− pz(c∗(z))| ≤ a4ξγ2 for sufficiently small ξ.
Assumption C is implied by a Ho¨lder continuity condition that describes the smoothness of
pz(x) around c∗(z).
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Before specifying Assumption D, we first define the metric entropy for any give set. For a
given class B of subsets of S and any  > 0, {(Gl1, Gu1 , · · · , Glm, Gum)} forms an -bracketing
set of B if for any G ∈ B there is a j such that Glj ⊂ G ⊂ Guj and max{1≤j≤m} d(Guj , Glj) ≤
, where d(·, ·) is a distance for any two subsets in S defined as d(G1, G2) = P (G1∆G2) and
G1∆G2 = (G1\G2)
⋃
(G2\G1). Then the metric entropy H(,B) of B is defined as the logarithm
of the cardinality of the -bracketing set of B of the smallest size. Let G(k) = {Gc = {(x, z) :
x− c(z) ≥ 0}, c ∈ F , J(c) ≤ k} ⊂ G(F) = {Gc = {(x, z) : x− c(z) ≥ 0}, c ∈ F , J(c) < +∞}.
Assumption D. For positive constants a5, a6 and a7, there exists some n > 0 such that
sup
{k≥1}
φ(n, k) ≤ a5n1/2,
where φ(n, k) =
∫ (8a6)1/2Lα/2(α+γ)
a7L
H1/2(u2/2,G(k))du/L and L = L(n, C, k) = min(2n +
λnJ0(k/2− 1), 1).
Theorem 2 Suppose that Assumptions A-D are met. For the estimated personalized MCID cˆ(z),
there exists positive constants a8 and a9 such that
P
(
|cˆ(Z)− c∗(Z)| ≥ (β2n log(1/β2n))
α2
α2+2
)
≤ 3.5 exp
(
− a8n(λnJ(c0))
α2+2
α2+1
)
+ a9(log(1/β
2
n))
−1.
provided that β2n ≥ 4λn max(J(c0), 1) with β2n = min(max(2n, 2sn+2a3aα24 δα2γ2n ), 1) and fz(c∗(z))
is bounded away from 0.
Corollary 1 Under the assumptions of Theorem 2, |cˆ(Z) − c∗(Z)| = Op((β2n log(1/β2n))
α2
α2+2 ),
provided that n(λnJ(c0))
α2+2
α2+1 is bounded away from 0.
Theorem 2 and Corollary 1 develop upper bounds for the estimation accuracy of the estimated
cˆ(z). The convergence rate β
2α2
α2+2
n in Corollary 1 depends on the value of δn, 2n, sn and λn. More
importantly, such results can be difficult to establish for the standard classification function g(x, z)
due to its lack of explicit estimation of c∗(z).
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5 Simulation
This section examines the proposed estimation methods for estimating MCID using simulated
examples. Two scenarios are considered. Scenario I focuses on the population-based MCID for all
patients, and scenario II focuses on the personalized MCID that varies among patients and relies on
each patient clinical profile. To assess the estimation performance, we report the estimated MCID
as well as the misclassification error (MCE) based on the testing set, which is defined as
MCE(cˆ) =
1
ntest
∑
i∈testing set
I(yi 6= sign(xi − cˆ(zi))),
where ntest denotes the size of the testing set, and cˆ(zi) = cˆ for the population-based MCID.
5.1 Scenario I: population-based MCID
Two simulated examples are examined.
Example 1. A random sample {(Xi, Yi); i = 1, · · · , n+2000} is generated as follows. First,Xi
is generated from Unif(−1, 1) and then Yi is generated from Bern((xi+1)/2). Next, a sample of
size n is randomly selected for training and the remaining 2000 samples are allocated for testing.
Example 2. A random sample {(Xi, Yi); i = 1, . . . , n+2000} is generated as follows. First, Xi
is generated from the mixture of two Gaussian distributions 0.7N(−1, 1) + 0.3N(1, 1) and then Yi
is generated from Bern(F (xi)), where F (xi) = P (X ≤ xi). Next, a sample of size n is randomly
selected for training and the remaining 2000 samples are allocated for testing.
In both examples, the training sizes are set as n = 250, 500 and 1000. Both examples are
replicated 100 times. The averaged performance measures of our proposed method and Shiu and
Gatsonis (2008) are reported in Table 1. In addition, the ideal MCID’s and their corresponding
misclassification errors are used as baseline for the comparison in Table 1.
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Table 1 about here
In both examples, our proposed method yields accurate MCID estimates that are very close to
the ideal MCID’s. The resulting MCE’s are also close to the MCE’s produced by using the ideal
MCID’s. The performance of the method by Shiu and Gatsonis appears to be less competitive.
Even with a large sample size n = 1000, their estimated MCID’s are still considerably different
from the ideal MCID’s.
5.2 Scenario II: personalized MCID
For personalized MCID, the MCE by using our proposed method with linear and Gaussian kernels
are examined. The linear kernel is defined as K(z1, z2) = zT1 z2, and the Gaussian kernel is defined
as K(z1, z2) = e−‖z1−z2‖
2/2σ2 , where the scale parameter σ2 is set as the median of pairwise
Euclidean distances within the training set. To optimize the performance of our proposed method,
a grid search by 5-fold cross validation is employed to select the tuning parameter λ. The grid for
all examples is set as {10(s−31)/10; s = 1, · · · , 61}. For illustration, three simulated examples are
examined with δ = 0.1.
Example 1. A random sample {(Xi, Yi, Zi); i = 1, · · · , n} is generated as follows. First, Zi’s
are independently generated from N2(µ, I2) with µ = (0, 0)T . Second, Xi’s are independently
generated from N(b + wT zi, 1), where b = 0 and w = (1, 2)T . Next, the response Yi is generated
from Bern(F (xi)), where F (xi) = P (Xi ≤ xi).
Example 2. A random sample {(Xi, Yi, Zi); i = 1, · · · , n} is generated as follows. First, Zi’s
are independently generated from N2(µ, I2) with µ = (0, 0)T . Second, Xi’s are independently
generated from N(b + wT zi − wT z2i , 1), where b = 0 and w = (1, 2)T . Next, the response Yi is
generated from Bern(F (xi)), where F (xi) = P (Xi ≤ xi).
Example 3. A random sample {(Xi, Yi, Zi); i = 1, · · · , n} is generated as follows. First, Zi’s
are independently generated from N3(µ, I3)) with µ = (0, 0, 0)T . Second, Xi’s are independently
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generated from N(b + cos(wT zi), 1), where b = 0 and w = (1, 1.5, 2)T . Next, the response Yi is
generated from Bern(F (xi)), where F (xi) = P (Xi ≤ xi).
For each example, the training sizes are set as 100, 250, 500 and the testing size is set as 2000.
All examples are replicated 50 times, and the averaged test errors are reported in Table 2.
Table 2 here
Our proposed method delivers satisfactory performance in estimating the personalized MCID
in all three examples. In addition, the linear kernel yields slightly better performance than the
Gaussian kernel in Example 1 as the true classification boundary is linear, and it is outperformed by
the Gaussian kernel in the other two examples with nonlinear boundaries. Therefore, the Gaussian
kernel would be suggested if no prior knowledge about the boundary is available.
For estimating the personalized MCID, the choice of δ may impact the performance of our
proposed method. By Theorem 2, large δ leads to less accurate prediction while computational
instability may occur when small δ is used for the estimation. For illustration, we conducted a
sensitivity analysis on the values of δ in a random replication of Example 1 with training size 250.
The estimated coefficients and prediction error as functions of δ are displayed in Figure 1. It is
evident that when δ is too large, the estimation of c(z) moves away from the truth and yields a
larger error rate. When δ is close to 0, the error rate and estimation of c(z) are relatively stable.
Therefore, we recommend to set δ as 0.1 for simplicity.
Figure 1 about here
6 Real applications
In this section, our proposed method is applied to a phase-3 woman heavy menstrual blood loss
dataset (WHMBL) and a phase-3 hot flush dataset (Hot Flush).
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The WHMBL clinical trial aims to develop a treatment for reducing the amount of blood loss
during a menstrual cycle in excessive bleeding women. The primary efficacy variable is the change
from baseline in blood loss volume. The blood loss of each patient is measured per menstrual cycle
and the PRO’s are collected based on a questionnaire answered by each patient at a post-treatment
visit. The WHMBL trial dataset consists of 481 patients administered either placebo or active
doses. Patient profile contains the information of age, body mass index (BMI), alcohol (Yes/No),
tobacco (Yes/No) and baseline value of blood loss. The 481 patients were randomly split into a
training set of 240 patients and a testing set of 241 patients.
The hot flush clinical trial aims to develop a treatment for reducing hot flush in women due
to menopause. The hot flush clinical trial dataset consists of 1684 patients administered either
placebo or active doses. Patient profile contains the information for age, BMI, race and baseline
hot flushes. 300 patients were selected randomly to form the training set and the remaining 1384
patients were used as the testing set.
Here, δ = 0.1 is used for simplicity and the tuning parameter λ is selected as in Section 5.2.
Each example is replicated 50 times, and Table 4 summarizes the averaged performance measures
of the method by Shiu and Gatsonis, the population-based MCID, and the personalized MCID with
the linear and Gaussian kernels.
Table 3 about here
In both scenarios, our proposed method delivers competitive performance in comparison with
the method by Shiu and Gatsonis. In WHMBL trial, the method by Shiu and Gatsonis yields a neg-
ative MCID which is clinically misleading. It is also interesting to notice that for the WHMBL trial,
personalized MCID yields larger MCE when compared with population-based MCID. It could be
due to the homogeneity among the enrolled patients. For the hot flush trial, patients’ satisfaction
on treatment effect is more accurately estimated when the clinical profiles are included. A closer
investigation of the fitted classification function implies that patients’ satisfaction is highly affected
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by the baseline hot flushes. This is reasonable as patients with higher baseline hot flushes tend to
expect better treatment effect.
7 Closing remarks
This paper proposes a general framework for formulating as well as estimating population-based
and personalized MCID’s. The concept of MCID has attracted much attention in clinical trials,
while little statistical work has been done for appropriately determining MCID. Our proposed
method unifies both population-based and personalized MCID’s into a large margin classification
framework, and delivers superior estimation performance in both simulated examples and real
applications to two phase-3 clinical trials. More importantly, the asymptotic properties of our
proposed method are established for both population-based and personalized MCID’s. Future
research work will focus on the potential issues when applying our proposed MCID’s to various
clinical trials.
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Appendix A: technical proofs
Proof of Lemma 1. Note that c∗ is a solution of
min
c
1
2
E
(
1− Y sign(X − c)) = min
c
1
2
EX
(
1− E(Y |X) sign(X − c)),
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where EX represents the expectation with respect to X . It then suffices to find c∗ to maximize
E(Y |X = x) sign(x− c) for any given x. Therefore, c∗ must satisfy that
sign(x− c) = sign(E(Y |X = x)) = sign(2p(x)− 1), (16)
for any x, where p(x) = P (Y = 1|X = x). We now show contradiction when p(c∗) 6= 1/2.
Without loss of generality, assume p(c∗) > 1/2. Since p(x) is continuous and monotone in x,
there must exist c˜ such that p(c˜) = 1/2 and c˜ < c∗. This leads to the contradiction to (16) since
0 > sign(c˜− c∗) = sign(2p(c˜)− 1) = 1.
Therefore, c∗ must satisfies p(c∗) = 1
2
. Furtheremore, when p(x) is continuous and strictly increas-
ing, the uniqueness follows from the fact that p(c∗) = 1
2
has a unique solution.
Proof of Theorem 1. We first show that cˆ p−→ c∗. Let Fy(x) = P (X ≤ x, Y = y), then
1
2
E (1− Y sign(X − c)) = P (X ≤ c, Y = 1) + P (X > c, Y = −1)
= F1(c) + P (Y = −1)− F−1(c).
By strong law of large number, 1
n
∑n
i=1 I(Yi = −1) a.s.−→ P (Y = −1). Further, it follows from
Theorem 19.1 of Van der Vaart (1998) that
F1,n(c) =
1
n
n∑
i=1
I(Xi ≤ c, Yi = 1) a.s.−→ F1(c),
F−1,n(c) =
1
n
n∑
i=1
I(Xi ≤ c, Yi = −1) a.s.−→ F−1(c),
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uniformly over c. Therefore,
1
2n
n∑
i=1
(1− yi sign(xi − c)) a.s.−→ 1
2
E (1− Y sign(X − c))
uniformly over c. Also by Lemma 1, 1
2
E (1− Y sign(X − c)) has a unique minimizer c∗ when
p(x) is continuous and strictly increasing in x. The desired asymptotic consistency follows imme-
diately after Theorem 5.7 of Van der Vaart (1998).
Next, we establish the convergence rate of |cˆ − c∗| by using Theorem 5.52 of Van der Vaart
(1998). We just need to verify the necessary assumptions. Note that c∗ is the minimizer of 1
2
E(1−
y sign(x− c)). Without loss of generality, for any c > c∗, direct deviation yields that
E(mc(X, Y )−mc∗(X, Y )) = P (c∗ ≤ X < c, Y = 1)− P (c∗ ≤ X < c, Y = −1)
=
∫ c
c∗
p(x)f(x)dx−
∫ c
c∗
(1− p(x))f(x)dx
=
∫ c
c∗
(2p(x)− 1)f(x)dx,
where mc(x, y) = 12(1− y sign(x− c)).
Since f(x) is continuous at c∗, it can be shown that P (c∗ ≤ X ≤ c∗ + ξ) ≥ a9ξ for sufficient
small ξ > 0, where a10 = f(c∗)/2 > 0. Furthermore, p(c∗ + ξ) − p(c∗) > (a10/a1)1/α1(ξ)2/α1 ,
since otherwise there exists 0 < ξ1 < 1 such that p(c∗ + ξ1) − p(c∗) ≤ (a10/a1)1/α1(ξ1)2/α1 , and
by assumption (4)
a10ξ1 ≤ P (c∗ ≤ X ≤ c∗ + ξ1) ≤ P
(
|p(X)− p(c∗)| ≤ (a10/a1)1/α1(ξ1)2/α1
)
≤ a10(ξ1)2,
which leads to a contradiction to the fact that ξ1 < 1.
Since p(x) in continuous in x, there exists 0 < ξ2 < ξ such that p(c∗ + ξ2) − p(c∗) =
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(a10/a1)
1/α1(ξ)2/α1 , and then
E(mc∗+ξ(X, Y )−mc∗(X, Y ))
=
∫ c∗+ξ
c∗
(2p(x)− 1)f(x)dx >
∫ c∗+ξ
c∗+ξ2
(2p(x)− 1)f(x)dx > (a10/a1)1/α1(ξ)2/α1
∫ c∗+ξ
c∗+ξ2
f(x)dx
= (a10/a1)
1/α1(ξ)2/α1
(
P (c∗ ≤ X ≤ c∗ + ξ)− P (c∗ ≤ X ≤ c∗ + ξ2)
)
≥ (a10/a1)1/α1(ξ)2/α1
(
P (c∗ ≤ X ≤ c∗ + ξ)− P (|p(X)− p(c∗)| ≤ (a10/a1)1/α1(ξ)2/α1)
)
≥ a1+1/α110 a−1/α11 ξ2/α1(ξ − ξ2).
It can be shown similarly that
E(mc∗−ξ(X, Y )−mc∗(X, Y )) ≥ a1+1/α110 a−1/α11 ξ2/α1(ξ − ξ2).
Therefore, there exists constant a11 > 0 such that for sufficiently small ξ > 0,
sup
|c−c∗|<ξ
E(mc(X, Y )−mc∗(X, Y )) ≥ a11ξ1+2/α1 . (17)
Furthermore, denote Fm = {mc(x, y)−mc∗(x, y) : x ∈ R, y ∈ {−1,+1}}. Consider the grid
−∞ = t1 < t1 < · · · < tk = +∞ with tdk/2e = c∗ and P (x < ti)− P (x ≤ ti−1) <  for each ti.
Note that
mc(x, y)−mc∗(x, y) =
 I(c
∗ ≤ x < c, y = −1)− I(c∗ ≤ x < c, y = 1), if c > c∗,
I(c < x ≤ c∗, y = 1)− I(c < x ≤ c∗, y = −1), if c ≤ c∗.
Then the functional brackets [1[c∗,ti](x), 1[c∗,ti+1)(x)] for i > dk/2e and [1[ti,c∗](x), 1(ti−1,c∗](x)] for
i ≤ dk/2e forms L1(P ) brackets of size  for Fm with cardinality k < 2/. Thus the bracketing
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number N[ ](,Fm, L2(P )) = O(−2) and then the bracketing integral
J[ ](η,Fm, L2(P )) =
∫ η
0
√
logN[ ](,Fm, L2(P ))d ≤ a12η log η,
for some constant a12 < 0.
Also g(x) = I(c∗− ξ ≤ x ≤ c∗+ ξ) is an envelop function of mc−mc∗ with |c− c∗| < ξ, and
then assumptions (4) and (5) imply that
‖g‖P,2 = (P (|X − c∗| ≤ ξ))1/2 ≤
(
P (|p(X)− p(c∗)| ≤ a2ξγ1)
)1/2 ≤ (a1aα12 )1/2ξα1γ1/2.
By Corollary 19.35 of Van der Vaart (1998),
E∗ sup
|c−c∗|<ξ
|Gn(mc −mc∗)| ≤ J[ ](‖g‖P,2,Fm, L2(P )) ≤ J[ ]((a1aα12 )1/2ξα1γ1 ,Fm, L2(P ))
≤ 1
2
a12α1γ1(a1a
α1
2 )
1/2ξα1γ1/2 log ξ.
Thereupon, denote A = 1 + 2/α1−α1γ1/2, it follows from Theorem 5.52 of Van der Vaart (1998)
that for a sufficiently large integer M ,
P ∗
(
|cˆ− c∗| ≥ 2M(n log−2 n)−1/(2A)
)
≤ 2
1+2/α1
a11A(2−A − 1)a12α1γ1(a1a
α1
2 )
1/22−MA. (18)
Proof of Lemma 2. For any given z, since Lδ(u) = L01(u) + δ−1(δ − u)I(0 ≤ u ≤ δ), we have
E
(
Lδ(Y (X − c(z)))|Z = z
)
= E
(
L01(Y (X − c(z)))|Z = z
)
+ E
(δ − Y (X − c(z))
δ
I(0 ≤ Y (X − c(z)) ≤ δ)|Z = z
)
.
(19)
Note that E
( δ−Y (X−c(z))
δ
I(0 ≤ Y (X − c(z)) ≤ δ)|Z = z) is decreasing in δ, and approaches 0
when δ → 0. Furthermore, E(L01(Y (X − c(z)))|Z = z) − E(L01(Y (X − c∗(z)))|Z = z) =
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∫ c(z)
c∗(z)(2pz(x) − 1)fz(x)dx, which is increasing in c(z) when c(z) > c∗(z). Therefore, there exist
δu(z) > 0 and cu(z) such that
∫ cu(z)
c∗(z)
(2pz(x)− 1)fz(x)dx ≥ E
(δu − Y (X − c)
δu
I(0 ≤ Y (X − c) ≤ δu)|Z = z
)
.
This implies that for any δ < δu(z), argmincE
(
Lδ(Y (X − c))|Z = z
)
≤ cu(z). Similarly,
there exist δl(z) and cl(z) such that for any δ < δl(z), argmincE
(
Lδ(Y (X − c))|Z = z
)
≥ cl(z).
Therefore, for any δ < min{δl(z), δu(z)}, argmincE
(
Lδ(Y (X−c))|Z = z
)
must lie in a compact
set D(z) around c∗(z).
The second term on the right hand side of (19) is bounded below by 0 and above by P
(
|X−c| ≤
δ|Z = z
)
and is decreasing in δ. Therefore, by Dini’s theorem, P
(
|X − c| ≤ δ|Z = z
)
converges
to 0 uniformly over D(z) as δ → 0. It further implies that E
(
Lδ(Y (X − c))|Z = z
)
converges
to E
(
L01(Y (X − c))|Z = z
)
uniformly over D(z) as δ → 0. This, together with the fact that
E
(
L01(Y (X − c))|Z = z
)
is convex in c, implies that
argmin
c
E
(
Lδ(Y (X − c(z)))|Z = z
)
−→ argmin
c
E
(
L01(Y (X − c(z)))|Z = z
)
= c∗(z),
when δ converges to zero.
Before delving into the proof of Theorem 2, we first define the L2- metric entropy with brack-
eting for a function class F . For any  > 0, {(ll1, lu1 ), · · · , (llm, lum)} forms an -bracketing of F ,
if for any c ∈ F , there is a j, such that llj ≤ l(c, ·) ≤ luj and max{1≤j≤m} ‖llj − luj ‖2 ≤ , where
‖ · ‖2 is the L2-norm. Then the L2-metric entropy of F with bracketing HB(,F) is defined as a
logarithm of the cardinality of the -bracketing of F of the smallest size.
Proof of Theorem 2. The proof consists of two steps. The first step establishes an upper bound
for the misclassification error e(cˆ, c∗) = E
(
L01(Y (X − cˆ(Z))) − L01(Y (X − c∗(Z)))
)
, and the
second step connects e(cˆ, c∗) with |cˆ(Z)− c∗(Z)| and attains the desired results.
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Step 1: First we introduce some notations. Let l˜δn(c,Di) = Lδn(yi(xi − c(zi))) + λJ(c),
where Di = (xi, yi, zi). Similarly, denote l˜(c,Di) = L01(yi(xi − c(zi))) + λJ(c). Then the scaled
empirical process En(l˜(c,D)− l˜δn(c0, D)) is defined as
En(l˜(c,D)− l˜δn(c0, D)) =
1
n
n∑
i=1
(
l˜(c,Di)− l˜δn(c0, Di)− E(l˜(c,Di)− l˜δn(c0, Di))
)
.
Since Lδn(yi(xi − c(zi))) ≥ L01(yi(xi − c(zi))) for any δn > 0, we have
l˜δn(c0, Di)− l˜(c,Di) ≥ l˜δn(c0, Di)− l˜δn(c,Di).
Furthermore, by Assumptions A-C,
e(c0, c
∗) = EL01(Y (X − c0(Z)))− EL01(Y (X − c∗(Z)))
≤ eδn(c0, c∗) + P
(
|pz(X)− pz(c∗(z))| ≤ a4δγ2n
)
≤ sn + a3aα24 δα2γ2n ≤ β2n/2.
Let cˆ = argmin
c∈F
1
n
n∑
i=1
l˜δn(c,Di) be the estimated personalized MCID, then
{e(cˆ, c∗) ≥ β2n} ⊂
{
sup
{e(c,c∗)≥β2n}
1
n
n∑
i=1
(
l˜δn(c0, Di)− l˜δn(c,Di)
)
≥ 0
}
⊂
{
sup
{e(c,c∗)≥β2n}
1
n
n∑
i=1
(
l˜δn(c0, Di)− l˜(c,Di)
)
≥ 0
}
.
It immediately implies that
P (e(cˆ, c∗) ≥ β2n) ≤ P ∗
(
sup
{e(c,c∗)≥β2n}
1
n
n∑
i=1
(
l˜δn(c0, Di)− l˜(c,Di)
)
≥ 0
)
=ˆI,
where P ∗ denotes the outer probability measure.
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Note that the functional space {c ∈ F : e(c, c∗) ≥ β2n} can be partitioned as
Aij = {c ∈ F : 2i−1β2n ≤ e(c, c∗) < 2iβ2n, 2j−1 max(J(c0), 1) ≤ J(c) < 2j max(J(c0), 1)};
Ai0 = {c ∈ F : 2i−1β2n ≤ e(c, c∗) < 2iβ2n, J(c) < max(J(c0), 1)},
for i = 1, 2, · · · and j = 1, 2, · · · . Then we need to establish some inequalities on the first and
second moments of l˜(c,D)− l˜δn(c0, D) for c ∈ Aij .
For the first moment, note that for any c ∈ F ,
E(L01(c,D)− Lδn(c0, D)) = E(L01(c,D)− L01(c∗, D)) + E(L01(c∗, D)− Lδn(c0, D))
≥ e(c, c∗) + eδn(c∗, c0)− a3aα24 δα2γ2n
≥ e(c, c∗)− sn − a3aα24 δα2γ2n ≥ e(c, c∗)− β2n/2.
Then with the assumption that λmax(J(c0), 1) ≤ β2n/4,
inf
Aij
E(l˜(c,D)− l˜δn(c0, D)) ≥ 2i−2β2n + (2j−1 − 1)λJ(c0) = M(i, j), (20)
inf
Ai0
E(l˜(c,D)− l˜δn(c0, D)) ≥ (2i−1 − 3/4)β2n ≥ 2i−3β2n = M(i, 0). (21)
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For the second moment, it follows from Assumptions B and C that for any c ∈ F ,
e(c, c∗) = E|pZ(X)− 1/2| |sign(X − c∗(Z))− sign(X − c(Z))|
≥ ξE |sign(X − c∗(Z))− sign(X − c(Z))| I(|pZ(X)− 1/2| ≥ ξ)
≥ ξ (E| sign(X − c∗(Z))− sign(X − c(Z))| − 2a3ξα2)
≥ 2−1−2/α2a−1/α23 (E| sign(X − c∗(Z))− sign(X − c(Z))|)(1+α2)/α2
= 2−1−2/α2a−1/α23 (E|L01(c∗, D)− L01(c,D)|)(1+α2)/α2 ,
with a choice of ξ = (E| sign(X − c∗(Z)) − sign(X − c(Z))|/4a6)1/α2 . Now we are ready to
establish an upper bound for the second moment. Note that for any d, L01(c,D) ≤ Lδn(c,D),
then E(|L01(c0, D)−Lδn(c0, D)|) = E(Lδn(c0, D)−L01(c0, D)) = E(Lδn(c0, D)−Lδn(c∗, D)+
Lδn(c
∗, D)− L01(c0, D)) ≤ eδn(c0, c∗) + a3aα24 δα2γ2n . Therefore, by the triangular inequality,
E (l(c,D)− lδn(c0, D))2 ≤ E(|l(c,D)− lδn(c0, D)|)
≤ E|l(c∗, D)− l(c,D)|+ E|l(c∗, D)− l(c0, D)|+ E|l(c0, D)− lδn(c0, D)|
≤ E|l(c∗, D)− l(c,D)|+ E|l(c∗, D)− l(c0, D)|+ eδn(c0, c∗) + a3aα24 δα2γ2n
≤ 21+2/α2a1/α23 (e(c, c∗)α2/(1+α2) + e(c0, c∗)α2/(1+α2)) + eδn(c0, c∗) + a3aα24 δα2γ2n
≤ a6(e(c, c∗))α2/(1+α2),
where a6 = 22+2/α2a
1/α2
3 + 1, and the last inequality is due to the fact that e(c, c
∗) ≥ β2n ≥
eδn(c0, c
∗) + a3a
α2
4 δ
α2γ2
n ≥ e(c0, c∗) for any c ∈ Aij . Consequently,
sup
Aij
E (l(c,D)− lδn(c0, D))2 ≤ v2(i, j)=ˆ8a6M(i, j)α2/(1+α2),
where i = 1, 2, · · · and j = 0, 1, 2, · · · .
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Now we are ready to establish the upper bound of I . Using (20) and (21), we have
I ≤
∑
i,j
P ∗
(
sup
Aij
En(lδn(c0, D)− l(c,D)) ≥M(i, j)
)
+
∑
i
P ∗
(
sup
Ai0
En(lδn(c0, D)− l(c,D)) ≥M(i, 0)
)
=ˆI1 + I2.
Then we bound I1 and I2 separately by using Theorem 3 of Shen and Wong (1994), and we
just need to verify the conditions (4.5)-(4.7) therein. To compute the metric entropy in (4.7),
applying the same technique as in Shen et al. (2003) yields that HB(,F(2j)) ≤ H(2/2,G(2j))
for any  > 0 and j = 0, 1, · · · , where F(2j) = {l(c, d) − lδn(c, d) : c ∈ F , J(c) ≤ 2j}. Since∫ v(i,j)
a7M(i,j)
H1/2(u2/2,G(2j))du/M(i, j) is non-increasing in i and M(i, j), we have
∫ v(i,j)
a7M(i,j)
H1/2(u2/2,G(2j))du/M(i, j)
≤
∫ (8a6)1/2M(1,j)α2/2(α2+1)
a7M(1,j)
H1/2(u2/2,G(2j))du/M(1, j) ≤ φ(n, 2j),
where a7 = 1/64. Simply let  = 1/2, then Assumption D implies (4.7). Furthermore, (4.5) and
(4.6) are satisfied with the above choice of ,M(i, j), v(i, j) and T = 1. In more details, (4.7)
implies (4.5) and M(i, j)/v2(i, j) ≤ 1/8 implies (4.6).
Then Theorem 3 of Shen and Wong (1994) with M = n1/2M(i, j), v = v2(i, j),  = 1/2 and
T = 1 implies that
I1 ≤
+∞∑
j=1
+∞∑
i=1
3 exp
(
− nM(i, j)
2
4(4v2(i, j) +M(i, j)/3)
)
≤
+∞∑
j=1
+∞∑
i=1
3 exp
(
−a8nM(i, j)
α2+2
α2+1
)
≤
+∞∑
j=1
+∞∑
i=1
3 exp
(
−a8n[2i−2β2n + (2j−1 − 1)λJ(c0)]
α2+2
α2+1
)
≤ 3 exp
(
−a8n(λJ(c0))
α2+2
α2+1
)(
1− exp(−a8n(λJ(c0))
α2+2
α2+1 )
)−2
,
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where a8 is a positive constant. I2 can be bounded similarly, and thus
I ≤ 6 exp
(
−a8n(λJ(c0))
α2+2
α2+1
)(
1− exp(−a8n(λJ(c0))
α2+2
α2+1 )
)−2
,
which implies that I1/2 ≤ (2.5 + I1/2) exp
(
−a8n(λJ(c0))
α2+2
α2+1
)
. With I ≤ I1/2 ≤ 1, then
P
(
e(cˆ, c∗) ≥ β2n
)
≤ 3.5 exp
(
− a8n(λnJ(c0))
α2+2
α2+1
)
. (22)
Step 2: For any given z ∈ DZ , Assumptions B and C are similar to (4) and (5) in Theorem 1
and yield that for any sufficiently small ξ > 0, there exists a constant a9 > 0 such that
E
(
L01(Y (X − (c∗(z)± ξ))|Z = z
)
− E
(
L01(Y (X − c∗(z)))|Z = z
)
≥ a9ξ1+2/α2 ,
and E
(
L01(Y (X − (c∗(z) ± ξ))|Z = z
)
− E
(
L01(Y (X − c∗(z)))|Z = z
)
is monotonically
increasing with ξ. Therefore, conditional on the training data,
e(cˆ, c∗) ≥ E
(
{L01(Y (X − cˆ(Z)))− L01(Y (X − c∗(z)))}I(|cˆ(Z)− c∗(Z)| ≥ ξ)
)
≥ E
(
{L01(Y (X − (c∗(Z) + ξ sign(cˆ(Z)− c∗(Z)))))
−L01(Y (X − c∗(z)))}I(|cˆ(Z)− c∗(Z)| ≥ ξ)
)
≥ a9ξ1+2/α2E(I(|cˆ(Z)− c∗(Z)| ≥ ξ)) = a9ξ1+2/α2P (|cˆ(Z)− c∗(Z)| ≥ ξ).
We are now ready to bound P
(
|cˆ(Z)− c∗(Z)| ≥ (β2n log(1/β2n))
α2
α2+2
)
. By (22) and the above
inequality,
P
(
|cˆ(Z)− c∗(Z)| ≥ (β2n log(1/β2n))
α2
α2+2
)
= E
(
P
(|cˆ(Z)− c∗(Z)| ≥ (β2n log(1/β2n)) α2α2+2 ))
≤ E(a−19 β−2n log(1/β2n)−1e(cˆ, c∗)) ≤ 3.5 exp
(
− a8n(λnJ(c0))
α2+2
α2+1
)
+ a−19 (log(1/β
2
n))
−1.
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The desired results follow immediately after re-defining a9.
Appendix B: a counterexample for various losses
Consider a simple example where X is uniformly distributed on [a, b], p(x) is continuous and
strictly increasing, and min{c∗−a, b− c∗} > 1. By (2), c∗ is the unique MCID. On the other hand,
the minimizer of the hinge loss must satisfy that
∫ c∗+1
a
p(x)dx−
∫ b
c∗−1
(1− p(x))dx = 0,
the minimizer of the logistic loss must satisfy that
∫ b
a
(
p(x)− 1
1 + ec∗−x
)
dx = 0,
and the minimizer of the ψ-loss must satisfy that
∫ c∗+1
c∗−1
(
p(x)− 1
2
)
dx = 0.
These equalities do not hold in general. For instance, let p′′(x) = 0, when x ≥ c∗ and p′′(x) > 0
otherwise, then minimizers for all three losses are strictly larger than c∗.
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Table 1: Simulation I. Averaged MCID and the misclassification error (MCE) and their standard
errors (in parentheses) for our method (OUR) and the method by Shiu and Gatsonis (SG) based on
100 replications. The ideal performance is included as the baseline for comparison.
n=250 n=500 n=1000 Ideal
Example 1
OUR 0.055(0.0116) -0.021(0.0058) 0.004(0.0032)MCID
SG 0.078(0.0387) -0.065(0.0290) -0.080(0.0222)
0.000
OUR 0.260(0.0010) 0.255(0.0005) 0.253(0.0003)MCE
SG 0.344(0.0045) 0.355(0.0033) 0.374(0.0024)
0.250
Example 2
OUR -0.563(0.0187) -0.496(0.0095) -0.497(0.0056)MCID
SG -0.436(0.0827) -0.286(0.0676) -0.370(0.0526)
-0.514
OUR 0.257(0.0009) 0.253(0.0005) 0.252(0.0003)MCE
SG 0.338(0.0043) 0.361(0.0033) 0.374(0.0024)
0.250
Table 2: Simulation II. Estimated means and standard deviations (in parentheses) of the misclassi-
fication error by using our proposed method with linear and Gaussian kernels based on 50 replica-
tions.
n=100 n=250 n=500 Ideal
Example 1
Linear 0.256(0.0119) 0.254(0.0112) 0.250(0.0108)
Gaussian 0.280(0.0177) 0.270(0.0146) 0.259(0.0130)
0.250
Example 2
Linear 0.412(0.0146) 0.408(0.0140) 0.408(0.0095)
Gaussian 0.290(0.0169) 0.274(0.0133) 0.260(0.0118)
0.250
Example 3
Linear 0.315(0.0132) 0.313(0.0129) 0.318(0.0103)
Gaussian 0.323(0.0182) 0.308(0.0122) 0.293(0.0109)
0.250
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Table 3: Real applications. Averaged MCID and misclassification error (MCE) and their standard
errors(in parenthesis) by using the method by Shiu and Gatsonis (SG), the population-based MCID
(OUR), the personalized MCID with linear kernel (OURL) and Gaussian kernel (OURG) based on
50 replications.
SG OUR OURL OURG
WHMBL
MCID -45.004(3.3011) 20.610(0.4905) - -
MCE 0.436(0.0016) 0.358(0.0014) 0.365(0.0186) 0.376(0.0185)
Hot Flush
MCID 5.426(0.4453) 6.060(0.0229) - -
MCE 0.399(0.0049) 0.282(0.0005) 0.260(0.0054) 0.268(0.0031)
Figure 1: Sensitivity analysis of δ in a randomly selected replication of Example 1 with n = 250.
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